Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 22, 2003

View Archived Issues

Atrix and Elan terminate pain management joint venture

Evidence of antitumor efficacy for SRL-712 and IL-2 in advanced melanoma

Fast track designation awarded to Advexin for head & neck cancer

Improved endothelial function following one year of genistein in postmenopausal women

Potential role for acetylcholinesterase inhibitors in neurogenic orthostatic hypotension

Clinical benefits of topical PTH(1-34) cream in chronic plaque psoriasis

Atorvastatin improves walking distance in patients with peripheral artery disease

Potential of liposteroids in the treatment of hemophagocytic syndrome related to SLE

Investigational HIV prime-boost vaccination evaluated in phase I trial

Dow and Sunol collaborate on plant-based production of antibody for cancer

CytRx to form Araios subsidiary with focus on obesity and type 2 diabetes

Keryx enters first SOAR collaboration for KRX-101

SBIR grant awarded for clinical trials of rhLF for diabetic foot ulcers

Eisai submits E.U. Pariet application for on-demand therapy of symptomatic GERD

Six-month priority review granted for Eloxatin sNDA

R&D progress at Celltech Group

New muscarinic M3 antagonists for use in asthma, COPD, etc.

Kv1.5 potassium channel blockers presented by BMS and ICAgen

Bayer scientists prepare and test novel anticytomegalovirus compounds

Novel benzamidine-based factor Xa inhibitors in Morphochem pipeline

Axon patent covers new aripiprazole analogues for schizophrenia and other uses

Novel PTP inhibitors in early development at Applied Research Systems

RWJ-442831, a new water-soluble prodrug of an anti-MRSA cephalosporin

Anti-MRSA carbapenems obtained by Korean scientists

GSK investigates prodrug strategies for delivery of new NNRTIs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...